Pravachol
(Pravastatin)ApprovedSmall molecule
Pravastatin is used to lower cholesterol and reduce the risk of heart disease and stroke by helping your body produce less cholesterol and clear it from your bloodstream more effectively.[2] Pravachol is currently approved and in use across 31 indications[4].[1]
Pravachol is one of 731 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.
31
Indications
108
Total Trials
6
Active Trials
730
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 31 indications
Competition
Competitive Landscape
702 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Statin16 trials
Show 13 more trials
Effect of Statin Use on Aldosterone Secretion
Completed·—·Phase 1·NCT02871687·103 enrolled
Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126)
Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 4·NCT00117494·86 enrolled
Statin Distribution
Completed·—·Phase 1·NCT02360826·32 enrolled
Interaction6 trials
Cilostazol-Simvastatin Drug Interaction Study
Unknown status·—·Phase 1·NCT02431013·20 enrolled
Preeclampsia4 trials
Efficacy and Safety3 trials
Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced Hepatocarcinoma
Completed·—·Phase 2·NCT01418729·216 enrolled
Atorvastatin3 trials
66 more indications
Acute Coronary Syndrome3 trials
Autosomal Dominant Polycystic Kidney Disease2 trials
Fibrosis2 trials
Endothelial Dysfunction2 trials
Atherosclerosis2 trials
Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)
Completed·—·Phase 2·NCT00054938·150 enrolled
Tics2 trials
Cholesterol2 trials
Coronary Artery Disease2 trials
Peritoneal Dialysis1 trial
Single Dose Pravastatin Pharmacokinetics in Pediatric Peritoneal Dialysis Patients
Terminated·—·Phase 1·NCT00571194·7 enrolled
Drug Metabolism1 trial
Combined hyperlipidemia1 trial
Stroke1 trial
Japan Statin Treatment Against Recurrent Stroke (J-STARS)
Completed·TTranslational Research Center for Medical Innovation, Kobe, Hyogo, Japan·Phase 3·NCT00221104·1,578 enrolled
Relapsing-Remitting Multiple Sclerosis1 trial
Nephrotic Syndrome1 trial
Heart Attack1 trial
Hyperlipidemia1 trial
Left Ventricular Hypertrophy1 trial
Diabetes1 trial
High Potency Statins and the Risk of Diabetes
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02518503·136,966 enrolled
Acute Kidney Injury1 trial
High Potency Statins and Acute Kidney Injury
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02518516·2,067,639 enrolled
Major Adverse Cardiac Events1 trial
Hermansky-Pudlak syndrome1 trial
Drug Interactions1 trial
Fasting Conditions1 trial
Acute Myeloid Leukemia1 trial
Schizophrenia1 trial
Hepatocellular Carcinoma1 trial
Esophageal Cancer1 trial
Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer
Unknown status·—·Phase 4·NCT01038154·146 enrolled
Cardiomyopathy1 trial
Type 2 Diabetes1 trial
Monotherapy1 trial
Methotrexate1 trial
Optical Coherence Tomography1 trial
Heart Transplantation1 trial
Tuberculosis1 trial
Familial Hypercholesterolemia1 trial
Endometriosis1 trial
Statins: A New Therapeutic Option for Treatment of Patients With Endometriosis
Withdrawn·—·N/A·NCT02079974
Acute Myocardial Infarction1 trial
Progeria1 trial
A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
Completed·—·Phase 2·NCT00879034·5 enrolled
Homozygous Familial Hypercholesterolemia1 trial
Liver Disease1 trial
Injury1 trial
Pravastatin as a Prophylactic to Reduce Endothelial Injury in Pediatric Patients With Elevated Body Mass Index
Completed·—·Phase 1·NCT05524246·25 enrolled
Schizoaffective Disorder1 trial
Chronic Kidney Disease1 trial
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
Completed·—·Phase 4·NCT02992548·62 enrolled
Leukemia1 trial
Lymphedema1 trial
Fibrosis Syndrome1 trial
Unspecified2 trials
A Phase 1 Clinical Trial in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Embibatinib, the Effects of Food, Acid-Reducing Agents, and Drug-Drug Interactions, and the Relative Bioavailability of New Tablet Formulations of Embibatinib.
Completed·TTerns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·Phase 1·NCT07838987·196 enrolled
Regulatory
FDA Approval Timeline[5]
Oct 31, 1991
PRAVACHOL
NDA NDA019898
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Pravachol drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Pravastatin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details